Healthcare Industry News:  ultrasound 

Devices Distribution

 News Release - June 23, 2014

Itamar Medical Ltd. signs strategic marketing and distribution agreement for its EndoPAT(TM) device with premier medical device maker Nihon Kohden Japan

The agreement follows in the wake of two recently concluded strategic agreements with Philips and Medtronic

The EndoPAT™ device, employed in non-invasive assessment of arterial health, provides indications used to assess the risk of cardiovascular events


CAESAREA, Israel--(Healthcare Sales & Marketing Network)--Medical device manufacturer Itamar Medical Ltd. announced today that Nihon Kohden (TSE:6849), one of Japan's largest medical device manufacturers, will distribute the EndoPAT™ device as their leading product for endothelial function assessment, and will market the EndoPAT™ to hospitals and to over 100,000 general practitioners in Japan. The agreement may contribute to Itamar Medical's operations in Japan with sales expected to rise.

The exclusive distribution agreement was reached after Nihon Kohden concluded that testing with Itamar Medical's EndoPAT™ device provides unique and important indications in assessing the risk of cardiovascular events. The agreement comes a year after Itamar Medical's subsidiary launched operations in Japan, posting steady revenue growth there.

The EndoPAT™ device is used in non-invasive assessment of arterial health through the assessment of endothelial function (the inner lining of blood vessels), which regulates vasodilation and vasoconstriction. The test takes 15 minutes. A thimble-like sensor is placed on a patient finger on each hand and a blood pressure cuff temporarily stops blood flow to the arm to measure the arterial reaction and expansion once blood flow resumes. Unlike complex ultrasound-based tests, the innovative EndoPAT™ device is unique in offering ease of use and accurate information that is not reliant on the competency of the testing staff and the doctor who interprets the results.

Over the past year, Itamar Medical has diversified beyond sales from targeted research institutions to major clinical care organizations, focusing on patients with symptoms and diagnosed conditions, which dovetail with Nihon Kohden's marketing to doctors and cardiologists in Japan. Nihon Kohden is also committed to providing customers with clinical and technical support.

The agreement comes on the heels of two strategic marketing agreements concluded with Philips' local representative in Japan and with Medtronic, a giant medical device maker in the United States, both related to Itamar Medical's WatchPAT™ acclaimed sleep diagnostic device.

Itamar Medical CEO Gilad Glick: "The agreement with Nihon Kohden is testimony to their confidence in our product and its clinical and commercial potential. This agreement, along with the Philips agreement in the sleep breathing disorder market, will allow Itamar Medical to accelerate market penetration in Japan where Nihon Kohden is a leader in the cardiology market. With Japan constituting one of the major and most sophisticated medical device markets in the world, we consider Nihon Kohden to be an outstanding partner for accelerating clinical use of EndoPAT™ testing. The Japanese market is currently the most advanced in adapting clinical use of endothelial function assessment in the patient care strategy. Given the approved insurance reimbursement scheme for this test in Japan, the extensive ongoing academic and research activity there, and the inclusion of the EndoPAT™ test in the Japanese guidelines for assessing vascular function, we see significant potential in this deal."

Itamar Medical VP Sales Eldad Singer noted: "Nihon Kohden is the ideal partner for distribution of EndoPAT™ in Japan, due to its leading stature among cardiologists and general practitioners. The agreement, signed for three years, may be extended. It stipulates aggressive sales and growth targets as a condition for exclusivity."

Itamar Medical Ltd. is a publicly traded medical device company (ITMR.TA) based in Caesarea’s Industrial Park, Israel. Since its founding in 1998, Itamar Medical has engaged in research and development of non-invasive medical devices for diagnosis of various medical conditions, including cardiovascular disease and sleep breathing disorders.

Nihon Kohden is a leading manufacturer, developer and distributor of electronic medical devices in Japan. Nihon Kohden's international operations include branches in the United States, Europe and Asia, as well as distributors in other markets worldwide. In 2013, Nihon Kohden sales exceeded USD 1.4 billion. In Japan, Nihon Kohden's distribution network comprises of 120 offices throughout the country. Nihon Kohden is considered a leading provider of cardiology equipment (including ECG), emergency medical equipment, as well as sports healthcare and rehabilitation equipment.

This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the Company’s ability to establish and maintain corporate collaborations; (ii) the implementation of the Company’s business model, strategic plans for its business and therapeutic candidates; (iii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (iv) estimates of the Company’s expenses, future revenues capital requirements and the Company’s needs for additional financing; and (v) competitive companies, technologies and the Company’s industry. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.


Source: Itamar Medical

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps 2 - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps 2 - available on the Apple App Store for iPhone and iPad.